Improving Docetaxel Treatment for Prostate Cancer
Enhancing the Efficacy of Docetaxel in Prostate Cancer
This project aims to understand why some men with advanced prostate cancer don't respond well to docetaxel chemotherapy and how to make the treatment work better for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11137135 on NIH RePORTER |
What this research studies
For men with advanced prostate cancer, docetaxel chemotherapy is a vital treatment, but not everyone benefits equally, and resistance can develop. This project looks into the reasons behind this resistance by studying how the drug works at a cellular level. Researchers are exploring specific markers, like the FOXJ1 gene, which appear to be linked to whether a patient responds to docetaxel. By understanding these biological clues, the goal is to find new ways to overcome resistance and improve treatment outcomes.
Who could benefit from this research
Good fit: This work is most relevant to men with metastatic castration-resistant prostate cancer (mCRPC) or castration-sensitive metastatic prostate cancer (mCSPC) who are receiving or considering docetaxel chemotherapy.
Not a fit: Patients with early-stage prostate cancer not requiring chemotherapy or those with other cancer types would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies or combinations of treatments that make docetaxel more effective for men with advanced prostate cancer, potentially prolonging their lives.
How similar studies have performed: Previous work by this team has identified mechanisms of taxane resistance in both patients and mouse models, providing a strong foundation for this current investigation.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Balk, Steven P. — Beth Israel Deaconess Medical Center
- Study coordinator: Balk, Steven P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.